DISEASE SCANNER

Global Incurable Diseases Tracker

Back to Globe
Infectious Disease

Onchocerciasis (River Blindness)

HIGH SEVERITY

A parasitic disease caused by the nematode worm Onchocerca volvulus, transmitted through the bites of infected blackflies. Leading cause of infectious blindness worldwide. Affects approximately 20-25 million people, primarily in sub-Saharan Africa. WHO goal is elimination by 2030.

Global Affected

20.0M

Countries

51

Symptoms

Severe itching
Skin nodules
Skin rash
Skin thickening
Skin depigmentation (leopard skin)
Eye lesions
Blindness
Visual impairment
Lymphadenopathy
Hanging groin
Sowda (severe localized itching)
Elephantiasis of scrotum

Treatment Options

Ivermectin (annual/biannual)
Moxidectin (single dose)
Doxycycline (6-week course)
Skin nodule removal
Symptomatic treatment for itching
Eye surgery if needed
Skin care
Supportive care

Risk Factors

1Living near fast-flowing rivers
2Living in endemic areas
3Occupational exposure (farming, fishing)
4Repeated blackfly bites
5Rural residence
6Agricultural work
7Outdoor activities near rivers

Diagnostic Methods

  • 1Skin snip biopsy
  • 2Serological tests
  • 3PCR testing
  • 4Slit-lamp examination (eye)
  • 5Nodule palpation
  • 6Mazzotti test (diagnostic challenge)
  • 7Ophthalmoscopy

Prognosis

Good with treatment. Ivermectin prevents blindness but does not reverse existing eye damage. Lifelong treatment may be needed in endemic areas. Skin disease can improve with treatment. Elimination programs showing success. Without treatment, progressive blindness occurs.

Prevention

  • Mass drug administration
  • Vector control (blackfly elimination)
  • Avoiding blackfly bites
  • Protective clothing
  • Insect repellents
  • Ivermectin treatment
  • Environmental management
  • Community-directed treatment programs

Research Status

Ivermectin (Mectizan) is the main treatment. Mass drug administration programs highly successful. Doxycycline to kill Wolbachia bacteria (symbiont). Vector control through blackfly elimination. Moxidectin newer treatment option. Elimination feasible by 2030.

Sources

  • https://www.who.int/health-topics/onchocerciasis
  • https://www.cdc.gov/parasites/onchocerciasis
  • https://www.hematology.org/education/patients
  • https://www.ncbi.nlm.nih.gov/books
  • https://rarediseases.org/rare-diseases

Medical Disclaimer

This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.